Comparing Arthroscopic Tennis Elbow Release With Arthroscopic Debridement

Overview

We propose a randomized, double-blind controlled trial comparing arthroscopic release with arthroscopic debridement for the management of chronic tennis elbow in an effort to definitively determine whether arthroscopic tennis elbow release is an effective treatment of tennis elbow, and to further provide better recommendations for the use of this procedure, in an effort to improve patient care.

Full Title of Study: “A Randomized, Double-blind Controlled Trial Comparing Arthroscopic Tennis Elbow Release With Arthroscopic Debridement for the Management of Chronic Lateral Epicondylitis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Outcomes Assessor)
  • Study Primary Completion Date: June 2025

Detailed Description

Lateral epicondylitis (tennis elbow) is a common occurrence in the general population with an incidence of 4-7/1000/year. More recent literature describes a 1-3% rate over the course of a lifetime, most typically affecting individuals between the ages of 35 and 50. Tennis elbow is a common occurrence in the general population that causes lateral elbow pain and diminished grip strength, which may be debilitating. Most affected individuals achieve symptom resolution within 6 months to 1 year with measures such as physiotherapy, anti-inflammatories and corticosteroid injections, but a small subset will go on to develop chronic symptoms. Chronic tennis elbow can be treated surgically, by arthroscopic tennis elbow release (ATER), which has gained popularity in recent years as it presents a less invasive option, allows for direct visualization of the elbow joint for other pathology and has a faster return-to-work time compared to other surgical procedures. Despite its promise there have been no high quality studies evaluating the efficacy of arthroscopic tennis elbow release, bringing the actual efficacy of this procedure into question. A randomized controlled trial on arthroscopic tennis elbow release would provide much needed evidence in order to define its role in the management of tennis elbow and to help refine treatment protocols.

Interventions

  • Procedure: Non operative
    • no surgical intervention
  • Procedure: Arthroscopic tennis elbow release
    • Patients randomized to Arthroscopic tennis elbow release (ATER) will receive arthroscopic release of the origin of the extensor carpi radialis brevis tendon through a standard, two-portal arthroscopic technique (medial and lateral).

Arms, Groups and Cohorts

  • Active Comparator: Arthroscopic tennis elbow release
    • This group will have arthroscopic tennis elbow release through a standard, two-portal technique,
  • Placebo Comparator: Non Operative
    • control group will not undergo a second portal or muscle release.

Clinical Trial Outcome Measures

Primary Measures

  • Change in Mayo Elbow Performance Score
    • Time Frame: From baseline to up until 24-Months Post-Operative
    • The Mayo Elbow Performance score is an outcome measure specific to the elbow to assess activities of daily living (ADLs). This outcome measure consists of 4 subscales: pain, range of motion, stability and daily function. Each section is combined for a total score out of 100 points. A higher score, indicates a better outcome.

Secondary Measures

  • Change in Disabilities of the Arm, Shoulder and Hand (DASH)
    • Time Frame: From baseline to up until 24-Months Post-Operative
    • The Disabilities of the Arm, Shoulder and Hand (DASH), is a questionnaire that measures physical function and symptoms in those with an upper extremity disorder. The DASH is a 30 item questionnaire, each question is rated using a Likert scale. The question points are combined for a total of 100 points. A higher score indicates a worse outcome.
  • Change in American Shoulder and Elbow Surgeons Elbow (ASES)
    • Time Frame: From baseline to up until 24-Months Post-Operative
    • The ASES is a shoulder specific assessment divided into two sections: pain and activities of daily living (ADL). Pain is recorded on a visual analogue scale (0-10), lower scores indicate better outcomes. There are 10 activities of daily living questions, each are recorded on a 4 level likert scale (0-3), which a higher score indicates a better outcome. The overall score is an equal weight of the two sections and produces a score out of 100. The higher the score, the better the outcome.
  • Change in Oxford Elbow Score (OES)
    • Time Frame: From time of enrollment up until 2-years post-operative
    • The Oxford Elbow Score (OES) is an outcome measure specific to patients who have had elbow surgery. The OES consists of 12 questions, looking into 3 domains: elbow function, pain, and social-psychological, using a Likert scale. Questions are summed, for a total score of 100 points. A higher score indicates a better outcome.
  • Change in Grip Strength
    • Time Frame: From time of enrollment up until 2-years post-operative
    • Grip strength will be measured using a hand-held dynamometer. Each participant will be asked to squeeze as much as they are comfortably able for approximately 3 seconds. 3 trials will be completed on each hand. Results will be averaged, and recorded in kilograms. Higher strength is a better outcome.
  • Adverse Events
    • Time Frame: Ongoing from time of enrollment, up until 24-months post-operative
    • Rates of study adverse events or serious adverse events (e.g. number of reoperations) will be monitored and recorded and compared between study groups. A higher rate of adverse events indicates a worse outcome.

Participating in This Clinical Trial

Inclusion Criteria

  • Symptoms consistent with lateral epicondylitis persisting for >6 months, and have failed conservative management – Adult, skeletally mature (>18yrs) – Provision of informed consent Exclusion Criteria:

  • Alternative diagnosis that better explain their symptoms – Previous elbow trauma or surgery – Case involving workplace insurance claims (e.g. WSIB) – Unwilling, or unlikely in the opinion of the investigator to be followed for the duration of the study (e.g., patient refusal, unfixed address, plans to move…etc.) – Cognitive difficulties that prevent ability to provide informed consent and reliable completion of questionnaires – Bilateral lateral epicondylitis

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ottawa Hospital Research Institute
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • J W Pollock, MD, Principal Investigator, The Ottawa Hospital
  • Overall Contact(s)
    • J W Pollock, MD, 613-737-8899

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.